For patients with NETs, somatostatin receptors are often targeted for nuclear theranostics applications. Investigators compared the benefits of a nomogram with the AJCC staging system in predicting overall survival. NETTER-2 is the first randomized study to demonstrate the efficacy of RLT as a 1L treatment for any form of cancer. Physicians currently have a limited understanding of how to properly diagnose and treat type 1 gastric NETs. Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients. A study found key tumor heterogeneities, including Ki-67 indices, might contribute to disease progression in GEP-NETs. Lu-177-dotatate in PRRT appeared to treat GEP-NETs, though prior internal radiation may impede responses or worsen survival. Researchers identified a circRNA signature as a potential biomarker for GEP-NETs. Patients with advanced stage gastroenteropancreatic neuroendocrine tumors appear to benefit from PRRT. The authors of the study won the 2022 SNMMI Abstract of the Year Award.